Secondary outcome measures at six weeks and six months after randomisation according to treatment group
| Physiotherapy | Injection | |
|---|---|---|
| *IQR, interquartile range; | ||
| †subjects not achieving maximum (180°) active abduction; | ||
| ‡subjects with restriction of >50% compared with non-involved arm. | ||
| Shoulder pain in day (median (IQR*)) | ||
| Baseline | 5 (4–7) | 5 (4–6) |
| 6 Weeks | 3 (1–4) | 3 (1–5) |
| 6 Months | 1 (0–3) | 2 (0–3) |
| Shoulder pain at night (median (IQR*)) | ||
| Baseline | 5 (3–7) | 5 (3–7) |
| 6 Weeks | 2 (1–4) | 3 (0–6) |
| 6 Months | 1 (0–3) | 1 (0–4) |
| Function (median (IQR*)) | ||
| Baseline | 4 (2–6) | 3.5 (2–5) |
| 6 Weeks | 3 (1–4) | 3 (1.5–5) |
| 6 Months | 1 (0–3) | 2 (0–4) |
| Main complaint (median (IQR*)) | ||
| Baseline | 52 (38–77) | 54 (43–74) |
| 6 Weeks | 26 (10–53) | 35 (17–57) |
| 6 Months | 11 (2–36) | 24 (8–53) |
| EuroQol (median (IQR*)) | ||
| Baseline | 0.66 (0.26–0.76) | 0.69 (0.52–0.76) |
| 6 Weeks | 0.76 (0.66–0.80) | 0.76 (0.59–0.80) |
| 6 Months | 0.76 (0.69–0.88) | 0.76 (0.66–1.00) |
| Restricted active abduction† (% yes) | ||
| Baseline | 78 (76) | 76 (73) |
| 6 Weeks | 40 (40) | 53 (54) |
| 6 Months | 31 (31) | 38 (39) |
| Restricted active external rotation‡ (% yes) | ||
| Baseline | 22 (21) | 9 (9) |
| 6 Weeks | 8 (8) | 12 (12) |
| 6 Months | 7 (7) | 8 (8) |
| Restricted passive external rotation‡ (% yes) | ||
| Baseline | 14 (14) | 7 (7) |
| 6 Weeks | 7 (7) | 7 (7) |
| 6 Months | 5 (5) | 6 (6) |